Rothschild & Co Upgrades MoonLake to Buy, Raises Price Target to $40
3/19/2026
Impact: 85
Healthcare
Rothschild & Co analyst Qize Ding has upgraded MoonLake (NASDAQ: MLTX) from Neutral to Buy. The price target for the stock has been raised significantly from $12 to $40.
AI summary, not financial advice
Share: